199 related articles for article (PubMed ID: 37932277)
21. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Byron SA; Loch DC; Wellens CL; Wortmann A; Wu J; Wang J; Nomoto K; Pollock PM
Mol Cancer; 2012 Oct; 11():75. PubMed ID: 23039341
[TBL] [Abstract][Full Text] [Related]
22. PKCalpha-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-beta1.
Chen Y; Yu G; Yu D; Zhu M
J Exp Clin Cancer Res; 2010 Aug; 29(1):104. PubMed ID: 20684793
[TBL] [Abstract][Full Text] [Related]
23. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
24. MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Das A; Henderson FC; Alshareef M; Porto GBF; Kanginakudru I; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
Clin Transl Oncol; 2021 Mar; 23(3):612-619. PubMed ID: 32710211
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Kim JH; Kim WS; Park C
BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
[TBL] [Abstract][Full Text] [Related]
26. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
27. Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells.
Pal S; Shankar BS; Sainis KB
Cytokine; 2013 Oct; 64(1):196-207. PubMed ID: 23972545
[TBL] [Abstract][Full Text] [Related]
28. HDAC-mediated control of ERK- and PI3K-dependent TGF-β-induced extracellular matrix-regulating genes.
Barter MJ; Pybus L; Litherland GJ; Rowan AD; Clark IM; Edwards DR; Cawston TE; Young DA
Matrix Biol; 2010 Sep; 29(7):602-12. PubMed ID: 20470885
[TBL] [Abstract][Full Text] [Related]
29. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Villanueva J; Vultur A; Lee JT; Somasundaram R; Fukunaga-Kalabis M; Cipolla AK; Wubbenhorst B; Xu X; Gimotty PA; Kee D; Santiago-Walker AE; Letrero R; D'Andrea K; Pushparajan A; Hayden JE; Brown KD; Laquerre S; McArthur GA; Sosman JA; Nathanson KL; Herlyn M
Cancer Cell; 2010 Dec; 18(6):683-95. PubMed ID: 21156289
[TBL] [Abstract][Full Text] [Related]
30. TGF-β may control the switch between tumorigenic growth and "stem cell/mesenchymal" potentially drug-resistant states.
Bordelon JR; Grichnik JM
Dermatol Ther; 2015; 28(3):177-8. PubMed ID: 25649199
[No Abstract] [Full Text] [Related]
31. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
32. Cooperative induction of receptor tyrosine kinases contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway.
Alver TN; Heintz KM; Hovig E; Bøe SL
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1736. PubMed ID: 36251678
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of hTERT and Cyclin D1 transcription via PI3K/Akt and TGF-β pathways in MCF-7 Cancer cells with PX-866 and Raloxifene.
Peek GW; Tollefsbol TO
Exp Cell Res; 2016 May; 344(1):95-102. PubMed ID: 27017931
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E; Khalighfard S; Amiriani T; Khori V; Alizadeh AM
Cell Oncol (Dordr); 2022 Dec; 45(6):1073-1117. PubMed ID: 36149600
[TBL] [Abstract][Full Text] [Related]
35. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
36. PI3K signalling is required for a TGFβ-induced epithelial-mesenchymal-like transition (EMT-like) in human melanoma cells.
Schlegel NC; von Planta A; Widmer DS; Dummer R; Christofori G
Exp Dermatol; 2015 Jan; 24(1):22-8. PubMed ID: 25363503
[TBL] [Abstract][Full Text] [Related]
37. Phosphatidylinositol 3-kinase/Akt pathway is involved in transforming growth factor-beta1-induced phenotypic modulation of 10T1/2 cells to smooth muscle cells.
Lien SC; Usami S; Chien S; Chiu JJ
Cell Signal; 2006 Aug; 18(8):1270-8. PubMed ID: 16310342
[TBL] [Abstract][Full Text] [Related]
38. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
39. Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition.
Sha J; Bai Y; Ngo HX; Okui T; Kanno T
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208465
[TBL] [Abstract][Full Text] [Related]
40. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
